Skip to main content
MyDeficiencies

Diphenoxylate/atropine

antimotility antidiarrheal, opioid-class with anticholinergic

Also sold as Lomotil.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Diphenoxylate/atropine has no established classical depletion machinery. Diphenoxylate is cleared by ester hydrolysis to the active metabolite difenoxine, then excreted in feces and urine; the label text retrieved names no CYP enzyme, no induction or inhibition, no renal tubular effect, and no mineral, vitamin or antacid interaction [1][2][3]. The one nutrient-relevant mechanism present is the intended one: slowed GI transit. That could in theory change absorption time, but no source retrieved measured a nutrient in a diphenoxylate/atropine cohort. The subtherapeutic atropine (0.025 mg per tablet) is addressed as a component, and no atropine-specific nutrient data were found.

antimotility antidiarrheal, opioid-class with anticholinergic · ATC A07DA01 (WHO ATC/DDD Index [4]; includes combinations with atropine) · also sold as Lomotil; many generics · reviewed 2026-10-04. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Diphenoxylate/atropine in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Fluid and electrolytes (indication-linked context flag; label caution, not a drug-caused nutrient loss)

Yellow — Low

See study details

The label tells prescribers to correct dehydration and electrolyte imbalance before and during use. The imbalance comes from the diarrheal illness being treated; no study opened measured an electrolyte in a diphenoxylate/atropine cohort.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key null findings: No label statement, case report or trial retrieved links the drug itself to a measured electrolyte or mineral change. This is a null at retrieval level, not a negative study.
  • At-risk subgroups: Children (contraindicated under 6 years; one infant with opioid toxicity was first misdiagnosed as dehydration [8]), people with severe or prolonged diarrhea, ulcerative colitis, and advanced hepatorenal disease [1][3].
  • Counter-evidence on record: Confounding by indication applies in full (Hard Rule 6): electrolyte disturbance is present before the drug is started in the population treated.

Regulatory status

All three label versions opened carry the fluid and electrolyte instruction. Exact wording in the Mylan label: "The use of diphenoxylate hydrochloride and atropine sulfate should be accompanied by appropriate fluid and electrolyte therapy, when indicated. If severe dehydration or electrolyte imbalance is present, diphenoxylate hydrochloride and atropine sulfate should be withheld until appropriate corrective therapy has been initiated." [2]. The Pfizer Lomotil label carries the first sentence [3]; the ANI label, as summarized by the fetch tool, says severe dehydration requires withholding treatment until corrected [1]. Labels also list megacolon, paralytic ileus, vomiting and nausea among adverse reactions, and warn of toxic megacolon in ulcerative colitis [1][3].

Population evidence

None measuring an electrolyte. The overdose case report in a 3-year-old (35 tablets) reported blood results "within normal limits" apart from a neutrophil percentage and gave no electrolyte values [7].

Mechanism

No renal or gut electrolyte-wasting mechanism is described in the label text retrieved. The intended action is slowed GI transit [1][3]. The flag arises from the underlying diarrhea (fluid, potassium, sodium, magnesium and bicarbonate loss are properties of the illness, not findings about this drug) and from motility-related complications the label names.

Counter-evidence held on record

Framing caution for the consumer surface This is a hydration and illness-severity flag, not a statement that the drug removes minerals. It does not imply that any mineral or electrolyte supplement should be added; correction of fluid and electrolyte losses is a clinical matter for the treating prescriber.

Toxin-mediated or antibiotic-associated diarrhea (retained-pathogen safety context; not a measured gut microbiome change)

Yellow — Low

See study details

Slowing gut transit in diarrhea caused by toxin-producing bacteria or by an antibiotic can worsen the illness. This is a clinical safety flag about infection, not evidence that the drug changes microbiome composition.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key null findings: No source opened measured microbiome composition, diversity or function in diphenoxylate/atropine users. Stool microbiota was not an endpoint in [6].
  • At-risk subgroups: People on antibiotics with new diarrhea, people with possible C. difficile or other toxigenic infection, and people with acute ulcerative colitis [1][3][6].
  • Counter-evidence on record: The outcome in [6] is GI irritation, a clinical outcome, so it cannot be filed as dysbiosis (Hard Rule 2). Confounding by the antibiotic exposure is deliberate in that design, which limits generalization to other diarrheas.

Regulatory status

Contraindicated in diarrhea associated with Clostridium difficile or enterotoxin-producing bacteria; warns of serious GI complications, including sepsis, in infectious diarrhea, and of toxic megacolon in ulcerative colitis, with prompt discontinuation if abdominal distention occurs [1][3].

Population evidence

Novak 1976, double-blind randomized study, 200 normal subjects, three-day regimens of lincomycin injection with placebo, atropine-diphenoxylate (Lomotil), an aspirin-phenacetin-caffeine combination or codeine: GI irritation was most pronounced with atropine-diphenoxylate; the author concluded its use for lincomycin-induced diarrhea "may be questionable." Abstract only was read; subject numbers per arm and effect sizes were not captured [6].

Mechanism

Named by the author as a hypothesis: reduced motility prolongs mucosal contact with the antibiotic and its toxic metabolites [6]. Label mechanism is segmentation and prolonged GI transit [1][3].

Counter-evidence held on record

Framing caution for the consumer surface Do not read this as a microbiome-damage claim. It is a reason to rule out infection before using an antimotility agent, a decision for a prescriber.

Riboflavin (antimuscarinic test-dose literature; class source identified but not read)

Not graded — disclosed evidence gap

See study details

A 1972 human study of the antimuscarinic propantheline and riboflavin absorption exists, but its result was not read and propantheline is not a component of this drug, so no riboflavin claim is made.

Full detail, limits and 1 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: The usual dual condition is strained here. A Tier C class source is known to exist, but it could not be opened, so it cannot support a yellow grade and cannot be cited for direction. No circulating riboflavin claim for this drug was found. The entry is held ungraded as a disclosed gap, and a revision that reads the paper should either grade it yellow (class extrapolation) or drop it. This is not a finding of safety.

What was searched

Crossref query "Levy propantheline riboflavin absorption" located Levy G, Gibaldi M, Procknal JA, J Pharm Sci 1972;61(5):798-799 [9]. OpenAlex single-record lookup returned metadata only: title, MeSH terms (Propantheline, Riboflavin, Intestinal Absorption, Parasympatholytics) and PMID 4556316; abstract field empty. PubMed record page, the Wiley page and the J Pharm Sci site returned no usable content (bot-verification or 403). Cohort test: the studied drug was propantheline; neither diphenoxylate nor atropine was named in the metadata, so any future reading would be Tier C class extrapolation for the atropine component only, capped at yellow, and the atropine content here (0.025 mg per tablet, labeled subtherapeutic) is small. Loperamide and other antimuscarinic siblings were not used. Revision pass: OpenAlex single-record lookup for PMID 4556316 re-opened (abstract field still null); PubMed listing for 4556316 opened and returned metadata only (MeSH Intestinal Absorption/drug effects; Riboflavin/metabolism/urine; no abstract), so the direction of the propantheline result remains unknown. Cohort test unchanged: propantheline, not diphenoxylate or atropine.

Channel outcomes

DailyMed label pages (three versions): opened, no statement on this topic as reported by the summarizing fetch tool. Crossref bibliographic search via WebFetch: opened, results listed in What was searched; it matches titles and metadata only, not abstracts or full text. PubMed search listing, PubMed record page, Europe PMC, Semantic Scholar, OpenAlex works-search, NCBI Bookshelf, scholar.archive.org: rate-limited (429), bot-verification, or empty shells. Springer, MDPI and PLOS search pages: robots.txt disallowed. WebSearch: session budget exhausted (200 of 200), so no consumer-claim search was possible. Direct curl to blocked databases was not attempted, per policy. Revision pass 2026-10-04: PubMed search-listing pages (format=pubmed view) opened for several queries and returned 429 for others (those pages were not retried); WebSearch remained exhausted; Europe PMC, Semantic Scholar and NCBI Bookshelf were not retried.

Gap type

Tooling-limited. Direction and size of the 1972 result are unknown to this review. Remains ungraded after a second attempt to open the abstract.

Classical vitamins and minerals not otherwise listed (B12, folate, vitamin D, calcium, zinc, magnesium, vitamin K)

Not graded — disclosed evidence gap

See study details

No diphenoxylate/atropine data on these nutrients were retrieved.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Dual condition: no Tier B or Tier C source supporting even a yellow grade was found or could be read, and no circulating consumer claim was found; the second half was only testable through label pages and a few guessed consumer URLs (Antidote Research, Drugs.com, MedlinePlus, all 404) because WebSearch was exhausted. This is a disclosed gap, not a finding of safety.

What was searched

Mechanism screen (below) found slowed transit as the only present absorption-related mechanism and no enzyme induction, renal wasting or chelation described in the label text retrieved. Crossref query "diphenoxylate vitamin deficiency OR malabsorption OR bacterial overgrowth" (20 results: B12 and bacterial overgrowth reviews and veterinary reports; none about diphenoxylate). The label summaries report no vitamin or mineral statements [2][3]. Revision pass: PubMed listings "Lomotil vitamin deficiency" (none mention Lomotil with a vitamin or mineral) and "diphenoxylate serum electrolytes" (one record, PMID 31280283, uses diphenoxylate only to induce constipation in rats in a polysaccharide and aquaporin study; no electrolyte, vitamin or mineral measurement on the drug). Two further combined queries (diphenoxylate with B12, folate, zinc, magnesium, calcium; Lomotil with hypokalemia or hyponatremia) returned 429 and were not retried.

Channel outcomes

DailyMed label pages (three versions): opened, no statement on this topic as reported by the summarizing fetch tool. Crossref bibliographic search via WebFetch: opened, results listed in What was searched; it matches titles and metadata only, not abstracts or full text. PubMed search listing, PubMed record page, Europe PMC, Semantic Scholar, OpenAlex works-search, NCBI Bookshelf, scholar.archive.org: rate-limited (429), bot-verification, or empty shells. Springer, MDPI and PLOS search pages: robots.txt disallowed. WebSearch: session budget exhausted (200 of 200), so no consumer-claim search was possible. Direct curl to blocked databases was not attempted, per policy. Revision pass 2026-10-04: PubMed search-listing pages (format=pubmed view) opened for several queries and returned 429 for others (those pages were not retried); WebSearch remained exhausted; Europe PMC, Semantic Scholar and NCBI Bookshelf were not retried.

Gap type

Tooling-limited. Chronic diarrhea itself, and conditions such as inflammatory bowel disease or short bowel, carry their own nutrient risks; those belong to the indication, not to this drug (Hard Rule 6). Re-searched in the revision with two phrasings; still no source naming this drug with a vitamin or mineral endpoint. Two queries remain untested because of rate limits.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden (animal evidence only: mitochondrial swelling or damage in constipation models that used diphenoxylate plus other stressors; confounded, not attributable to the drug alone)

Yellow — Low

See study details

Two animal constipation models that included compound diphenoxylate reported mitochondrial abnormalities by electron microscopy. Each model also used another constipating or stress exposure, so the finding is a weak mechanistic flag, not a drug effect.

Full detail, limits and 2 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key null findings: No diphenoxylate-only arm with a mitochondrial endpoint was found. No ATP, oxygen consumption or electron transport measurement appears in either abstract, so nothing here supports the ATP production entry (Hard Rule 7).
  • At-risk subgroups: None defined. No human data.
  • Counter-evidence on record: Hard Rule 2: ultrastructural mitochondrial swelling in colonic tissue of a constipation model is a tissue pathology outcome, not a nutrient deficiency and not a drug-specific mitochondrial toxicity finding. Both models are combination exposures. Shares the model-state mechanism with the Oxidative stress and Gut microbiome entries (see Overlap map).

Regulatory status

The labels contain no mitochondrial statement [1][2][3] (tool-reported negative).

Population evidence

Canine slow transit constipation model (PMID 29925160) [12]: the model group received a canned-meat diet plus compound diphenoxylate and alosetron hydrochloride for 5 weeks, controls a normal diet. Electron microscopy of colonic tissue showed "swelling of mitochondria" in myenteric neurons and interstitial cells of Cajal, with reduced PGP9.5 and synaptophysin. Abstract only; group sizes and journal were not captured. Rat model (Journal of Ethnopharmacology 2026, PMID 42521002) [13]: constipation with anxiety and depression was induced with compound diphenoxylate plus chronic unpredictable mild stress; the abstract states the herbal treatment "could inhibit mitochondrial damage by repairing mitochondrial structures" and inhibited the mitochondrial unfolded protein response, which implies mitochondrial damage in the model, but the abstract does not describe the control groups, so a model-versus-normal comparison was not confirmed. Tier B at best (animal studies including this drug); no effect estimate or confidence interval.

Mechanism

Not established. No source tested diphenoxylate, difenoxine or atropine on isolated mitochondria, respiration or membrane potential. Candidate drivers in the models are the constipated state, the co-administered alosetron, the diet (canine model) and chronic stress (rat model).

Counter-evidence held on record

Framing caution for the consumer surface This does not show that diphenoxylate/atropine harms mitochondria in people. It is a confounded animal-model flag, and it does not imply that any mitochondrial or energy supplement should be added.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress (animal evidence only: pro-oxidant marker shift in a diphenoxylate-induced constipation model in mice; not a human nutrient finding)

Yellow — Low

See study details

In mice given diphenoxylate to induce constipation, malondialdehyde rose and the antioxidant enzymes superoxide dismutase and glutathione peroxidase fell versus normal controls. This is a mechanistic animal signal in a model of the drug's own slowed-transit effect, with no human data.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key null findings: No human study measuring oxidative-stress markers in diphenoxylate/atropine users was found. The atropine component was not tested separately. A second listing hit, "Prebiotics and oxidative stress in constipated rats" (J Pediatr Gastroenterol Nutr 2011, PMID 21505362), uses diphenoxylate to induce constipation but its abstract was not opened (429), so it is not cited.
  • At-risk subgroups: None defined. The model uses healthy rodents at a dose chosen to induce constipation; no human population or human-equivalent exposure is implied.
  • Counter-evidence on record: Hard Rule 2 and Rule 6: an oxidative marker change in a constipation model is a model-state outcome, not a nutrient deficiency, and it is confounded by the constipation the drug is meant to cause. In humans the drug is used for diarrhea, so the direction of any confounding by indication is reversed. Not independent of the Gut microbiome risk entry (same experiment, see Overlap map).

Regulatory status

The labels opened contain no statement on oxidative stress or antioxidant status [1][2][3] (tool-reported negative).

Population evidence

Frontiers in Microbiology 2025 (PMID 41064254, DOI 10.3389/fmicb.2025.1672600), mouse study, n = 8 per group, six groups including normal control (NC) and model control (MC). The MC group received oral diphenoxylate 30 mg/kg body weight per day for three consecutive days. MC versus NC: MDA "significantly increased" (P < 0.01), SOD "significantly decreased" (P < 0.01), GSH-Px "significantly decreased" (P < 0.01). The sample matrix (serum, colon or other tissue) was not captured by the fetch summary. Full text was read through the WebFetch summarizer; effect sizes beyond the P values were not extracted [10]. Tier B (animal study using this drug); no confidence interval exists.

Mechanism

Not established. The direction is a pro-oxidative shift (higher lipid peroxidation product, lower antioxidant enzyme activity), the opposite of an antioxidant effect. The most plausible driver is the constipated state the drug was used to produce, not a direct redox action of diphenoxylate; this study has no non-diphenoxylate constipation control and no in vitro redox test of the drug.

Counter-evidence held on record

Framing caution for the consumer surface This is a rodent model finding, not evidence that diphenoxylate/atropine lowers antioxidant status in people. It does not imply that any antioxidant supplement should be added.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No diphenoxylate/atropine data on copper absorption, status or ceruloplasmin were retrieved. Copper is graded independently of Iron (Hard Rule 7).

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Dual condition: no Tier B or Tier C source supporting even a yellow grade was found or could be read, and no circulating consumer claim was found; the second half was only testable through label pages and a few guessed consumer URLs (Antidote Research, Drugs.com, MedlinePlus, all 404) because WebSearch was exhausted. This is a disclosed gap, not a finding of safety.

What was searched

Crossref query "diphenoxylate iron OR copper OR anemia OR hemoglobin" (20 results: infant anemia, iron therapy and hemoglobin papers; none involved diphenoxylate). Labels: no mention of copper (Mylan label as summarized by the fetch tool [2]). Revision pass: PubMed listing "diphenoxylate iron OR copper OR anemia" (10 results opened; copper deficiency, zinc, anemia and sideroblastic anemia papers, none mentioning diphenoxylate). No circulating copper claim for this drug was met.

Channel outcomes

DailyMed label pages (three versions): opened, no statement on this topic as reported by the summarizing fetch tool. Crossref bibliographic search via WebFetch: opened, results listed in What was searched; it matches titles and metadata only, not abstracts or full text. PubMed search listing, PubMed record page, Europe PMC, Semantic Scholar, OpenAlex works-search, NCBI Bookshelf, scholar.archive.org: rate-limited (429), bot-verification, or empty shells. Springer, MDPI and PLOS search pages: robots.txt disallowed. WebSearch: session budget exhausted (200 of 200), so no consumer-claim search was possible. Direct curl to blocked databases was not attempted, per policy. Revision pass 2026-10-04: PubMed search-listing pages (format=pubmed view) opened for several queries and returned 429 for others (those pages were not retried); WebSearch remained exhausted; Europe PMC, Semantic Scholar and NCBI Bookshelf were not retried.

Gap type

Tooling-limited, probable genuine gap at title level. Abstract-level search was not possible. Re-searched in the revision with a second phrasing; still no source naming this drug. Remains a probable genuine gap at title and abstract level.

Iron

Not graded — disclosed evidence gap

See study details

No diphenoxylate/atropine data on iron absorption, ferritin, iron deficiency or iron overload were retrieved. Iron is graded independently of Copper (Hard Rule 7).

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Dual condition: no Tier B or Tier C source supporting even a yellow grade was found or could be read, and no circulating consumer claim was found; the second half was only testable through label pages and a few guessed consumer URLs (Antidote Research, Drugs.com, MedlinePlus, all 404) because WebSearch was exhausted. This is a disclosed gap, not a finding of safety.

What was searched

Same Crossref iron/copper/anemia/hemoglobin query as Copper, with the same zero result. Labels: no mention of iron or anemia [2]. Note that the label lists no hematologic adverse reactions in the summaries retrieved; that is not a negative study. Revision pass: same PubMed listing as Copper (no diphenoxylate hit), plus "diphenoxylate constipation model hemoglobin OR ferritin OR serum iron" (10 results opened; iron metabolism and ferritin papers, none mentioning diphenoxylate), so the animal-model literature that uses diphenoxylate as a constipation inducer also reported no iron or hemoglobin endpoint in anything surfaced.

Channel outcomes

DailyMed label pages (three versions): opened, no statement on this topic as reported by the summarizing fetch tool. Crossref bibliographic search via WebFetch: opened, results listed in What was searched; it matches titles and metadata only, not abstracts or full text. PubMed search listing, PubMed record page, Europe PMC, Semantic Scholar, OpenAlex works-search, NCBI Bookshelf, scholar.archive.org: rate-limited (429), bot-verification, or empty shells. Springer, MDPI and PLOS search pages: robots.txt disallowed. WebSearch: session budget exhausted (200 of 200), so no consumer-claim search was possible. Direct curl to blocked databases was not attempted, per policy. Revision pass 2026-10-04: PubMed search-listing pages (format=pubmed view) opened for several queries and returned 429 for others (those pages were not retried); WebSearch remained exhausted; Europe PMC, Semantic Scholar and NCBI Bookshelf were not retried.

Gap type

Tooling-limited, probable genuine gap at title level. Re-searched in the revision with a second phrasing and a surrogate-endpoint query; still no source naming this drug. Remains a probable genuine gap at title and abstract level.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk (animal evidence only: lower diversity and a phylum shift in a diphenoxylate-induced constipation model in mice; not a human finding)

Yellow — Low

See study details

In mice given diphenoxylate to induce constipation, gut microbial alpha diversity was lower and the Bacteroidota to Bacillota balance shifted versus normal controls. It cannot be separated from the effect of slowed transit itself, and no human microbiome data exist for this drug.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key null findings: No human study of microbiota in diphenoxylate/atropine users was found; PubMed listing "diphenoxylate microbiota" returned animal constipation-model papers only. No study compared diphenoxylate with another constipating agent, so a drug-specific microbiome effect cannot be separated from constipation.
  • At-risk subgroups: None defined from these data. Healthy rodents, three-day exposure, dose chosen to induce constipation.
  • Counter-evidence on record: Hard Rule 2: a change in microbial composition in a model of constipation is not a nutrient deficiency, and it is not shown to be harmful. The yellow infection-context entry above rests on a separate source ([6] and the label) and measures illness, not microbiome; the two must not be read as confirming each other. In humans, treated diarrhea itself alters the microbiome (confounding by indication).

Regulatory status

Labels contain no microbiome statement. They carry contraindications and warnings for toxigenic and antibiotic-associated diarrhea, which are carried as a separate infection-context entry above [1][3].

Population evidence

Frontiers in Microbiology 2025 [10]: mouse study, n = 8 per group, diphenoxylate 30 mg/kg per day orally for three days. MC versus NC: Sobs, Ace, Chao, Simpson and Shannon indexes "decreased"; Bacteroidota "significantly lower relative abundance" (P < 0.005); Bacillota "significantly higher" (P < 0.005). Nutrients 2023 (PMID 37686774) [11]: abstract opened; in a diphenoxylate-induced slow transit constipation mouse model, the probiotic Lactiplantibacillus plantarum GUANKE "reduced constipation-induced Prevotella enrichment" and acted through specific taxa rather than diversity or short-chain fatty acids; the abstract did not give model-versus-normal data, group sizes or the dose. Many further rodent and canine papers use diphenoxylate only as the constipation inducer and test herbal or probiotic treatments; they were seen as titles or abstract excerpts and are not cited. Tier B (animal studies using this drug); no confidence intervals.

Mechanism

Not established. Slowed transit is the labeled pharmacologic effect [1][3] and is a known candidate driver of microbiota change; a direct antimicrobial or mucosal effect of diphenoxylate was not tested in any source opened. The atropine component was not tested separately.

Counter-evidence held on record

Framing caution for the consumer surface Do not present this as microbiome damage in people. It is a rodent constipation-model signal. It does not imply that a probiotic or prebiotic supplement is needed.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization (overdose and toxic-dose respiratory depression with hypoxia; a toxicity outcome, not an oxygen-carrying or nutrient deficiency)

Yellow — Low

See study details

In overdose or in young children the opioid component can depress breathing, causing hypoxia. This is a toxicologic outcome of the drug, and no hemoglobin, red-cell or tissue oxygen-utilization effect at therapeutic doses was found.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key null findings: No source opened measured hemoglobin, hematocrit, red-cell mass, 2,3-DPG or tissue oxygen utilization in a diphenoxylate/atropine cohort. The Mylan label summary reported no mention of anemia or oxygen [2].
  • At-risk subgroups: Children under 6 (contraindicated), infants and toddlers with accidental ingestion, people also taking alcohol, benzodiazepines, barbiturates or opioids (label CNS-depressant interaction), and people with Down syndrome (atropinism reported) [1][3].
  • Counter-evidence on record: Under Hard Rule 2, respiratory depression from an opioid is a drug toxicity outcome, not an oxygen-delivery deficiency and not a nutrient finding. It is carried as a context flag so the category is not left silent. It is not the drug's intended pharmacologic effect at labeled doses, and it is separate from ATP production (Hard Rule 7).

Regulatory status

Labels contraindicate use under 6 years because of respiratory and CNS depression and report "severe respiratory depression and coma, leading to permanent brain damage or death" in patients under 6; toxicity may be delayed up to 30 hours and respiratory depression may recur despite initial response to naloxone [1][3].

Population evidence

McCarron 1991, case series of 8 pediatric overdoses plus 28 literature cases (36 children): opioid CNS and respiratory depression predominated without atropine toxicity in 33 (92%); "diphenoxylate-induced hypoxia represented the major problem," with 3 deaths; respiratory depression recurred 13 to 24 hours after ingestion in 7 cases, probably from accumulation of difenoxine [5]. Abstract only was read. A single case report of a 3-year-old after 35 tablets describes respiratory arrest requiring CPR, with no blood-gas or oxygen-saturation values given [7]. A case report of an infant given an adult dose describes labored breathing and miosis reversed by naloxone [8]. No effect estimate with a confidence interval exists; these are descriptive series and reports (Tier B).

Mechanism

Named: mu-opioid effect of diphenoxylate and its active metabolite difenoxine on respiratory drive, with a half-life of difenoxine of about 12 to 14 hours and delayed absorption from prolonged gastric emptying [1][3][5][7].

Counter-evidence held on record

Framing caution for the consumer surface This is an overdose and pediatric safety signal, not a nutrient-status finding. There is nothing to supplement. The drug must be stored away from children, and suspected ingestion is a poison-control and emergency matter.

ATP production

Not graded — disclosed evidence gap

See study details

No data on mitochondrial ATP synthesis or cellular energy output in diphenoxylate/atropine users or models were retrieved. Graded independently of Mitochondrial burden and Oxygen delivery/utilization (Hard Rule 7).

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Dual condition: no Tier B or Tier C source supporting even a yellow grade was found or could be read, and no circulating consumer claim was found; the second half was only testable through label pages and a few guessed consumer URLs (Antidote Research, Drugs.com, MedlinePlus, all 404) because WebSearch was exhausted. This is a disclosed gap, not a finding of safety.

What was searched

Crossref mitochondrial and oxidative queries as above; no ATP, bioenergetic or oxidative-phosphorylation content. Respiratory depression in overdose is carried under Oxygen delivery/utilization as a toxicity outcome and is not used to infer ATP effects. Revision pass: PubMed listings "diphenoxylate constipation mitochondria OR mitochondrial OR ATP" and "diphenoxylate ATP OR oxidative phosphorylation OR respiration" (first 10 results of each opened; mitochondrial biology, ATP synthesis and respiration papers, none mentioning diphenoxylate). The mitochondrial swelling in animal constipation models [12][13] is an ultrastructure finding with no ATP or respiration measurement and is not used here (Hard Rule 7).

Channel outcomes

DailyMed label pages (three versions): opened, no statement on this topic as reported by the summarizing fetch tool. Crossref bibliographic search via WebFetch: opened, results listed in What was searched; it matches titles and metadata only, not abstracts or full text. PubMed search listing, PubMed record page, Europe PMC, Semantic Scholar, OpenAlex works-search, NCBI Bookshelf, scholar.archive.org: rate-limited (429), bot-verification, or empty shells. Springer, MDPI and PLOS search pages: robots.txt disallowed. WebSearch: session budget exhausted (200 of 200), so no consumer-claim search was possible. Direct curl to blocked databases was not attempted, per policy. Revision pass 2026-10-04: PubMed search-listing pages (format=pubmed view) opened for several queries and returned 429 for others (those pages were not retried); WebSearch remained exhausted; Europe PMC, Semantic Scholar and NCBI Bookshelf were not retried.

Gap type

Tooling-limited. Same single gap viewed three ways with Mitochondrial burden and Oxidative stress (see Overlap map). Re-searched with surrogate endpoints (oxidative phosphorylation, respiration); no ATP, respiration or energy-charge measurement with this drug was found. The yellow Mitochondrial burden entry does not extend to this entry.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • No circulating claim identified

    Where it comes from: Consumer-claim search was limited. WebSearch was exhausted for the session. Guessed consumer pages at Antidote Research (two paths), Drugs.com (three paths) and MedlinePlus returned 404, so no consumer depletion list for this drug was read.

    Why it fails: Nothing to rebut was found, which is not the same as no claim existing. Any consumer depletion claim for diphenoxylate/atropine that a later revision finds should be traced to its origin and either graded yellow (Tier B or C support) or listed here as white. Label summaries reported no vitamin, mineral, copper, iron, mitochondrial or oxygen content [1][2][3].

How the body handles this medication

Metabolism and enzymes (diphenoxylate)
Rapidly and extensively metabolized by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in blood. The label text retrieved names no CYP enzyme and describes no enzyme induction or inhibition; this negative comes through a summarizing tool.[1][2][3] DailyMed labels, clinical pharmacology
Elimination
After a 5 mg dose, an average of 14% of drug plus metabolites was excreted in urine and 49% in feces over four days. Peak plasma diphenoxylic acid averaged 163 ng/mL at about 2 hours after four 2.5 mg tablets; elimination half-life about 12 to 14 hours.[1][3]
Atropine component
Each tablet holds 2.5 mg diphenoxylate hydrochloride and 0.025 mg atropine sulfate; the atropine is a subtherapeutic amount intended to discourage overdosage. No atropine pharmacokinetics appear in the label text retrieved. Atropine is excreted in breast milk.[1][2][3]
Absorption and transit
Acts on circular smooth muscle of the bowel, producing segmentation and prolonged GI transit. Prolonged gastric emptying can delay onset of toxicity by up to 30 hours. No absorption transporter, food effect or antacid effect is described in the label text retrieved.[1][3][2]
Renal and hepatic handling
No effect on renal tubular handling of water or electrolytes and no renal dose adjustment is described in the label text retrieved. Extreme caution is advised in advanced hepatorenal disease because hepatic coma may be precipitated; contraindicated in obstructive jaundice.[1][2]
Documented interactions
Alcohol and other CNS depressants (barbiturates, benzodiazepines, opioids) potentiate CNS effects; MAO inhibitors risk hypertensive crisis given chemical similarity to meperidine. No mineral, vitamin or antacid interaction is listed.[1]

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

  • Clinical / hydration

    Fluid and electrolyte status

    If diarrhea is severe, prolonged, bloody or accompanied by vomiting, the label calls for fluid and electrolyte correction first. Serum sodium, potassium and magnesium are worth checking for the illness, not as a finding about the drug [2][3].

  • Duration

    Stop and reassess

    The label advises discontinuing if there is no clinical improvement within 10 days and reducing the dose once control is achieved [1]. Persistent diarrhea should prompt a look for the cause, including infection and nutrient malabsorption from the underlying disease.

  • Safety / infection

    Infectious diarrhea, colitis, antibiotics

    Contraindicated with C. difficile or enterotoxin-producing bacterial diarrhea. Abdominal distention, fever or bloody stool in colitis warrants prompt discontinuation and evaluation for toxic megacolon [1][3][6].

  • Respiratory / CNS

    Children and overdose

    Contraindicated under 6 years. Respiratory depression can be delayed up to 30 hours and can recur after naloxone, so ingestion needs emergency or poison-control assessment [1][3][5].

  • Timing

    Supplement separation

    No separation interval for any vitamin, mineral or antacid appears in the label text retrieved. Alcohol, MAO inhibitors and other CNS depressants are the documented interactions [1]. No supplement dose is recommended or appears anywhere in this dossier, so no NIH upper-limit comparison was needed.

  • Special populations

    Pregnancy, nursing, hepatic, Down syndrome

    Pregnancy use only if benefit justifies risk; the metabolite and atropine may pass into breast milk; extreme caution in advanced hepatorenal disease because hepatic coma may be precipitated; atropinism reported in children with Down syndrome [1]. Renal dosing is not given in the label text retrieved.

Overlap map, to prevent double counting

  • All label-based statements

    Shares evidence with: Labels [1], [2], [3]

    Note: Three DailyMed versions (ANI, Mylan, Pfizer Lomotil) of essentially one label text. They are not three independent Tier A sources. This is also why the red tier is empty.

  • Fluid and electrolytes

    Shares evidence with: Toxin-mediated or antibiotic-associated diarrhea

    Note: Both rest partly on the same Warnings section of the label [1][2][3]. The 1976 randomized study [6] is an independent source only for the second entry.

  • Oxygen delivery/utilization

    Shares evidence with: ATP production (ungraded); Mitochondrial burden (yellow)

    Note: Hypoxia from respiratory depression [1][3][5][7] is a toxicity outcome. It is not used as evidence of any mitochondrial or ATP effect. One source family, three conceptually adjacent categories.

  • Oxidative stress (yellow)

    Shares evidence with: Gut microbiome risk (yellow)

    Note: Both rest on the same experiment [10] (one mouse constipation model, MC versus NC), so they are one study counted twice, not two independent lines of evidence.

  • Mitochondrial burden (yellow)

    Shares evidence with: Oxidative stress; Gut microbiome risk; ATP production (ungraded)

    Note: Mitochondrial evidence [12][13] comes from different animal models than [10], but all three share one mechanism candidate: the constipated or stressed state, not a tested direct drug action. Neither [12] nor [13] measured ATP, so ATP production stays ungraded and shares only the same search channels.

  • Copper

    Shares evidence with: Iron

    Note: Same single Crossref query and the same label silence. Graded separately per Hard Rule 7; the gap is one gap viewed twice.

  • Gut microbiome risk (yellow)

    Shares evidence with: Toxin-mediated or antibiotic-associated diarrhea (yellow)

    Note: The infection-context entry rests on the label and the 1976 study [6] and contains no microbiome measurement; the microbiome entry rests on animal studies [10][11] and contains no infection outcome. They are independent in source and must not be read as confirming each other.

  • Riboflavin (ungraded)

    Shares evidence with: Classical vitamins and minerals (ungraded)

    Note: Riboflavin was split out because a named class paper [9] exists; the other nutrients rest on the same label silence and the same Crossref query.

All references used above
  1. Diphenoxylate hydrochloride and atropine sulfate tablets USP, ANI Pharmaceuticals, DailyMed label. — Regulatory label (Tier A). Description, clinical pharmacology, contraindications, warnings, overdosage, special populations. Revision date as reported by the fetch tool: 12/2025. Read through the WebFetch summarizer, not the raw page.
  2. Diphenoxylate hydrochloride and atropine sulfate tablets, Mylan Pharmaceuticals, DailyMed label. — Regulatory label (Tier A). Exact fluid and electrolyte wording; summarizer reported no mention of CYP, atropine pharmacokinetics, protein binding, food or antacid effects, renal impairment, vitamins, minerals, iron, copper, anemia, oxygen or mitochondria. Revision date as reported: February 2026. Negative statements are tool-reported.
  3. LOMOTIL (diphenoxylate hydrochloride and atropine sulfate) tablet, Pfizer Laboratories, DailyMed label. — Regulatory label (Tier A). Metabolism, excretion, half-life, toxic megacolon wording. Revision date as reported: March 2025. Summarizer reported no atropine pharmacokinetics, CYP interactions or nutrient content.
  4. WHO Collaborating Centre, ATC/DDD Index: diphenoxylate, A07DA01, DDD 15 mg oral. — Reference index. The page states that A07DA01 includes combinations with atropine. Read through the WebFetch summarizer.
  5. McCarron MM, Challoner KR, Thompson GA. Diphenoxylate-atropine (Lomotil) overdose in children: an update (report of eight cases and review of the literature). Pediatrics 1991;87(5):694-700. — Case series, 8 cases plus 28 literature cases (Tier B, this drug). DOI 10.1542/peds.87.5.694. Abstract only, reconstructed from OpenAlex through the fetch summarizer; full text not opened.
  6. Novak E. Unfavorable effect of atropine-diphenoxylate (Lomotil) therapy in lincomycin-caused diarrhea. JAMA 1976. — Double-blind randomized study, 200 normal subjects, five regimens (Tier A for its GI-irritation endpoint, not for nutrients or microbiome). DOI 10.1001/jama.1976.03260400017019. Abstract only, reconstructed from OpenAlex through the fetch summarizer; per-arm numbers not captured.
  7. Case report: multiple seizures after a diphenoxylate-atropine overdose in a small child. Front Pharmacol 2021. — Case report, one 3-year-old (35 tablets). DOI 10.3389/fphar.2021.646530. Full text read through the WebFetch summarizer; authors not captured.
  8. Khan HR, Kanwal S, Asghar SA, Qadar LT, Qadri KH. Diphenoxylate-atropine (Lomotil) toxicity in infantile diarrhea: a case report of therapeutic failure. Cureus 2019. — Case report, one infant. DOI 10.7759/cureus.5875. Abstract only, reconstructed from OpenAlex through the fetch summarizer.
  9. Levy G, Gibaldi M, Procknal JA. Effect of an anticholinergic agent on riboflavin absorption in man. J Pharm Sci 1972;61(5):798-799. — Human pharmacokinetic study of propantheline and riboflavin (class source, Tier C if read). DOI 10.1002/jps.2600610529; PMID 4556316 as given by OpenAlex. Only bibliographic metadata and MeSH terms were seen; the abstract and results were not opened.Not opened. Propantheline cohort; diphenoxylate and atropine not named in the metadata. Not used to support any grade or direction.
  10. Polysaccharide from Trichosanthes kirilowii Maxim ameliorates diphenoxylate-induced functional constipation in mice. Front Microbiol 2025. — Mouse study, n = 8 per group, normal control versus diphenoxylate model (30 mg/kg per day orally, 3 days) (Tier B, this drug as the constipation inducer). PMID 41064254; DOI 10.3389/fmicb.2025.1672600. Full text read through the WebFetch summarizer; authors not captured. Supports Oxidative stress and Gut microbiome risk (one experiment).
  11. Effects of Lactiplantibacillus plantarum GUANKE on Diphenoxylate-Induced Slow Transit Constipation and Gut Microbiota in Mice. Nutrients 2023. — Mouse study using diphenoxylate to induce slow transit constipation (Tier B, this drug as inducer). PMID 37686774. Abstract only, opened through the PubMed record listing and the fetch summarizer; group sizes, dose and model-versus-normal data not captured.Abstract only. Used only for the statement that the model produced Prevotella enrichment that the probiotic reduced; no effect sizes used.
  12. Establishment of a canine slow transit constipation model and evaluation of defecation, gastrointestinal transit and pathological sections. Chinese-language journal (name not captured); PMID 29925160. — Canine model, canned-meat diet plus compound diphenoxylate and alosetron for 5 weeks versus normal-diet controls (Tier B, this drug in combination with alosetron and diet; not attributable to diphenoxylate alone). Abstract only, opened through the PubMed record listing and the fetch summarizer; sample size not captured.Abstract only. Confounded by alosetron and diet. Supports only a yellow mechanistic flag for Mitochondrial burden.
  13. Shugan Tongbian Decoction ameliorates constipation and mental disorder by inhibiting UPR(mt) via Wnt/Retromer axis. J Ethnopharmacol 2026. — Rat model of constipation with anxiety and depression induced by compound diphenoxylate plus chronic unpredictable mild stress; herbal treatment study (Tier B at best, confounded by stress). PMID 42521002. Abstract only, opened through the PubMed record listing and the fetch summarizer; control groups not described in what was retrieved.Abstract only. No confirmed model-versus-normal mitochondrial comparison. Supportive of the canine finding only.